Home » TCR-Based Antibody Market
TCR-Based Antibody Market
Published date: Feb 2022 •Formats:
Request Sample Schedule a Call

Global TCR-Based Antibody Market Based on Target Antigen: (NY-ESO-1, p53, WT-1, EBv) Based on Indication: (Bladder Cancer, Multiple Myeloma) Based on End-Users: (Hospitals, Specialized Clinics, Gene Therapy Centers) and by Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032

  • Published date: Feb 2022
  • Report ID: 84335
  • Number of Pages: 227
  • Format:
  • keyboard_arrow_up
    • 1. Executive Summary
      • 1.1. Definition
      • 1.2. Taxonomy
      • 1.3. Research Scope
      • 1.4. Key Analysis
      • 1.5. Key Findings by Major Segments
      • 1.6. Top strategies by Major Players
    • 2. Global TCR-Based Antibody Overview
      • 2.1. TCR-Based Antibody Dynamics
        • 2.1.1. Drivers
        • 2.1.2. Opportunities
        • 2.1.2. Restraints
        • 2.1.4. Challenges
      • 2.2. Macro-economic Factors
      • 2.3. Regulatory Framework
      • 2.4. Market Investment Feasibility Index
      • 2.5. PEST Analysis
      • 2.6. PORTER’S Five Force Analysis
      • 2.7. Drivers & Restraints Impact Analysis
      • 2.8. Industry Chain Analysis
      • 2.9. Cost Structure Analysis
      • 2.10. Marketing Strategy
      • 2.11. Russia-Ukraine War Impact Analysis
      • 2.12. Opportunity Map Analysis
      • 2.13. Market Competition Scenario Analysis
      • 2.14. Product Life Cycle Analysis
      • 2.15. Opportunity Orbits
      • 2.16. Manufacturer Intensity Map
      • 2.17. Major Companies sales by Value & Volume
    • 3. Global TCR-Based Antibody Analysis, Opportunity and Forecast, 2016-2032
      • 3.1. Global TCR-Based Antibody Analysis, 2016-2021
      • 3.2. Global TCR-Based Antibody Opportunity and Forecast, 2023-2032
      • 3.3. Global TCR-Based Antibody Analysis, Opportunity and Forecast, By Target Antigen, 2016-2032
        • 3.3.1. Global TCR-Based Antibody Analysis by Target Antigen: Introduction
        • 3.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Target Antigen, 2016-2032
        • 3.3.3. NY-ESO-1
        • 3.3.4. p53
        • 3.3.5. WT-1
        • 3.3.6. EBv
      • 3.4. Global TCR-Based Antibody Analysis, Opportunity and Forecast, By Indication, 2016-2032
        • 3.4.1. Global TCR-Based Antibody Analysis by Indication: Introduction
        • 3.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Indication, 2016-2032
        • 3.4.3. Bladder Cancer
        • 3.4.4. Multiple Myeloma
        • 3.4.5. Ovarian Cancer
        • 3.4.6. Nasopharyngeal Carcinoma
        • 3.4.7. Acute Myeloid Leukemia
        • 3.4.8. Sarcoma
      • 3.5. Global TCR-Based Antibody Analysis, Opportunity and Forecast, By End-Users, 2016-2032
        • 3.5.1. Global TCR-Based Antibody Analysis by End-Users: Introduction
        • 3.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-Users, 2016-2032
        • 3.5.3. Hospitals
        • 3.5.4. Specialized Clinics
        • 3.5.5. Pharma & Biotech Research Laboratories.
        • 3.5.6. Gene Therapy Centers
    • 4. North America TCR-Based Antibody Analysis, Opportunity and Forecast, 2016-2032
      • 4.1. North America TCR-Based Antibody Analysis, 2016-2021
      • 4.2. North America TCR-Based Antibody Opportunity and Forecast, 2023-2032
      • 4.3. North America TCR-Based Antibody Analysis, Opportunity and Forecast, By Target Antigen, 2016-2032
        • 4.3.1. North America TCR-Based Antibody Analysis by Target Antigen: Introduction
        • 4.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Target Antigen, 2016-2032
        • 4.3.3. NY-ESO-1
        • 4.3.4. p53
        • 4.3.5. WT-1
        • 4.3.6. EBv
      • 4.4. North America TCR-Based Antibody Analysis, Opportunity and Forecast, By Indication, 2016-2032
        • 4.4.1. North America TCR-Based Antibody Analysis by Indication: Introduction
        • 4.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Indication, 2016-2032
        • 4.4.3. Bladder Cancer
        • 4.4.4. Multiple Myeloma
        • 4.4.5. Ovarian Cancer
        • 4.4.6. Nasopharyngeal Carcinoma
        • 4.4.7. Acute Myeloid Leukemia
        • 4.4.8. Sarcoma
      • 4.5. North America TCR-Based Antibody Analysis, Opportunity and Forecast, By End-Users, 2016-2032
        • 4.5.1. North America TCR-Based Antibody Analysis by End-Users: Introduction
        • 4.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-Users, 2016-2032
        • 4.5.3. Hospitals
        • 4.5.4. Specialized Clinics
        • 4.5.5. Pharma & Biotech Research Laboratories.
        • 4.5.6. Gene Therapy Centers
      • 4.6. North America TCR-Based Antibody Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 4.6.1. North America TCR-Based Antibody Analysis by Country : Introduction
        • 4.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 4.6.2.1. U.S.
          • 4.6.2.2. Canada
          • 4.6.2.3. Mexico
    • 5. Europe TCR-Based Antibody Analysis, Opportunity and Forecast, 2016-2032
      • 5.1. Europe TCR-Based Antibody Analysis, 2016-2021
      • 5.2. Europe TCR-Based Antibody Opportunity and Forecast, 2023-2032
      • 5.3. Europe TCR-Based Antibody Analysis, Opportunity and Forecast, By Target Antigen, 2016-2032
        • 5.3.1. Europe TCR-Based Antibody Analysis by Target Antigen: Introduction
        • 5.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Target Antigen, 2016-2032
        • 5.3.3. NY-ESO-1
        • 5.3.4. p53
        • 5.3.5. WT-1
        • 5.3.6. EBv
      • 5.4. Europe TCR-Based Antibody Analysis, Opportunity and Forecast, By Indication, 2016-2032
        • 5.4.1. Europe TCR-Based Antibody Analysis by Indication: Introduction
        • 5.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Indication, 2016-2032
        • 5.4.3. Bladder Cancer
        • 5.4.4. Multiple Myeloma
        • 5.4.5. Ovarian Cancer
        • 5.4.6. Nasopharyngeal Carcinoma
        • 5.4.7. Acute Myeloid Leukemia
        • 5.4.8. Sarcoma
      • 5.5. Europe TCR-Based Antibody Analysis, Opportunity and Forecast, By End-Users, 2016-2032
        • 5.5.1. Europe TCR-Based Antibody Analysis by End-Users: Introduction
        • 5.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-Users, 2016-2032
        • 5.5.3. Hospitals
        • 5.5.4. Specialized Clinics
        • 5.5.5. Pharma & Biotech Research Laboratories.
        • 5.5.6. Gene Therapy Centers
      • 5.6. Europe TCR-Based Antibody Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 5.6.1. Europe TCR-Based Antibody Analysis by Country : Introduction
        • 5.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 5.6.2.1. U.K.
          • 5.6.2.2. Germany
          • 5.6.2.3. France
          • 5.6.2.4. Spain
          • 5.6.2.5. Italy
          • 5.6.2.6. Russia
          • 5.6.2.7. Rest of Europe
    • 6. Asia-Pacific TCR-Based Antibody Analysis, Opportunity and Forecast, 2016-2032
      • 6.1. Asia-Pacific TCR-Based Antibody Analysis, 2016-2021
      • 6.2. Asia-Pacific TCR-Based Antibody Opportunity and Forecast, 2023-2032
      • 6.3. Asia-Pacific TCR-Based Antibody Analysis, Opportunity and Forecast, By Target Antigen, 2016-2032
        • 6.3.1. Asia-Pacific TCR-Based Antibody Analysis by Target Antigen: Introduction
        • 6.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Target Antigen, 2016-2032
        • 6.3.3. NY-ESO-1
        • 6.3.4. p53
        • 6.3.5. WT-1
        • 6.3.6. EBv
      • 6.4. Asia-Pacific TCR-Based Antibody Analysis, Opportunity and Forecast, By Indication, 2016-2032
        • 6.4.1. Asia-Pacific TCR-Based Antibody Analysis by Indication: Introduction
        • 6.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Indication, 2016-2032
        • 6.4.3. Bladder Cancer
        • 6.4.4. Multiple Myeloma
        • 6.4.5. Ovarian Cancer
        • 6.4.6. Nasopharyngeal Carcinoma
        • 6.4.7. Acute Myeloid Leukemia
        • 6.4.8. Sarcoma
      • 6.5. Asia-Pacific TCR-Based Antibody Analysis, Opportunity and Forecast, By End-Users, 2016-2032
        • 6.5.1. Asia-Pacific TCR-Based Antibody Analysis by End-Users: Introduction
        • 6.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-Users, 2016-2032
        • 6.5.3. Hospitals
        • 6.5.4. Specialized Clinics
        • 6.5.5. Pharma & Biotech Research Laboratories.
        • 6.5.6. Gene Therapy Centers
      • 6.6. Asia-Pacific TCR-Based Antibody Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 6.6.1. Asia-Pacific TCR-Based Antibody Analysis by Country : Introduction
        • 6.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 6.6.2.1. China
          • 6.6.2.2. Japan
          • 6.6.2.3. South Korea
          • 6.6.2.4. India
          • 6.6.2.5. Rest of Asia-Pacific
    • 7. South America TCR-Based Antibody Analysis, Opportunity and Forecast, 2016-2032
      • 7.1. South America TCR-Based Antibody Analysis, 2016-2021
      • 7.2. South America TCR-Based Antibody Opportunity and Forecast, 2023-2032
      • 7.3. South America TCR-Based Antibody Analysis, Opportunity and Forecast, By Target Antigen, 2016-2032
        • 7.3.1. South America TCR-Based Antibody Analysis by Target Antigen: Introduction
        • 7.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Target Antigen, 2016-2032
        • 7.3.3. NY-ESO-1
        • 7.3.4. p53
        • 7.3.5. WT-1
        • 7.3.6. EBv
      • 7.4. South America TCR-Based Antibody Analysis, Opportunity and Forecast, By Indication, 2016-2032
        • 7.4.1. South America TCR-Based Antibody Analysis by Indication: Introduction
        • 7.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Indication, 2016-2032
        • 7.4.3. Bladder Cancer
        • 7.4.4. Multiple Myeloma
        • 7.4.5. Ovarian Cancer
        • 7.4.6. Nasopharyngeal Carcinoma
        • 7.4.7. Acute Myeloid Leukemia
        • 7.4.8. Sarcoma
      • 7.5. South America TCR-Based Antibody Analysis, Opportunity and Forecast, By End-Users, 2016-2032
        • 7.5.1. South America TCR-Based Antibody Analysis by End-Users: Introduction
        • 7.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-Users, 2016-2032
        • 7.5.3. Hospitals
        • 7.5.4. Specialized Clinics
        • 7.5.5. Pharma & Biotech Research Laboratories.
        • 7.5.6. Gene Therapy Centers
      • 7.6. South America TCR-Based Antibody Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 7.6.1. South America TCR-Based Antibody Analysis by Country : Introduction
        • 7.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 7.6.2.1. Brazil
          • 7.6.2.2. Argentina
          • 7.6.2.3. Rest of South America
    • 8. Middle East and Africa TCR-Based Antibody Analysis, Opportunity and Forecast, 2016-2032
      • 8.1. Middle East and Africa TCR-Based Antibody Analysis, 2016-2021
      • 8.2. Middle East and Africa TCR-Based Antibody Opportunity and Forecast, 2023-2032
      • 8.3. Middle East and Africa TCR-Based Antibody Analysis, Opportunity and Forecast, By Target Antigen, 2016-2032
        • 8.3.1. Middle East and Africa TCR-Based Antibody Analysis by Target Antigen: Introduction
        • 8.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Target Antigen, 2016-2032
        • 8.3.3. NY-ESO-1
        • 8.3.4. p53
        • 8.3.5. WT-1
        • 8.3.6. EBv
      • 8.4. Middle East and Africa TCR-Based Antibody Analysis, Opportunity and Forecast, By Indication, 2016-2032
        • 8.4.1. Middle East and Africa TCR-Based Antibody Analysis by Indication: Introduction
        • 8.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Indication, 2016-2032
        • 8.4.3. Bladder Cancer
        • 8.4.4. Multiple Myeloma
        • 8.4.5. Ovarian Cancer
        • 8.4.6. Nasopharyngeal Carcinoma
        • 8.4.7. Acute Myeloid Leukemia
        • 8.4.8. Sarcoma
      • 8.5. Middle East and Africa TCR-Based Antibody Analysis, Opportunity and Forecast, By End-Users, 2016-2032
        • 8.5.1. Middle East and Africa TCR-Based Antibody Analysis by End-Users: Introduction
        • 8.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-Users, 2016-2032
        • 8.5.3. Hospitals
        • 8.5.4. Specialized Clinics
        • 8.5.5. Pharma & Biotech Research Laboratories.
        • 8.5.6. Gene Therapy Centers
      • 8.6. Middle East and Africa TCR-Based Antibody Analysis, Opportunity and Forecast, By Country , 2016-2032
        • 8.6.1. Middle East and Africa TCR-Based Antibody Analysis by Country : Introduction
        • 8.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
          • 8.6.2.1. GCC
          • 8.6.2.2. Israel
          • 8.6.2.3. South Africa
          • 8.6.2.4. Rest of MEA
    • 9. Global TCR-Based Antibody Analysis, Opportunity and Forecast, By Region , 2016-2032
      • 9.1. Global TCR-Based Antibody Analysis by Region : Introduction
      • 9.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Region , 2016-2032
        • 9.2.1. North America
        • 9.2.2. Europe
        • 9.2.3. Asia-Pacific
        • 9.2.4. South America
        • 9.2.5. Middle East and Africa
    • 10. Global TCR-Based Antibody Competitive Landscape, Market Share Analysis, and Company Profiles
      • 10.1. Market Share Analysis
      • 10.2. Company Profiles
      • 10.3. GlaxoSmithKline
        • 10.3.1. Company Overview
        • 10.3.2. Financial Highlights
        • 10.3.3. Product Portfolio
        • 10.3.4. SWOT Analysis
        • 10.3.5. Key Strategies and Developments
      • 10.4. Adaptimmune Therapeutics PLC
        • 10.4.1. Company Overview
        • 10.4.2. Financial Highlights
        • 10.4.3. Product Portfolio
        • 10.4.4. SWOT Analysis
        • 10.4.5. Key Strategies and Developments
      • 10.5. Celgene Corporation
        • 10.5.1. Company Overview
        • 10.5.2. Financial Highlights
        • 10.5.3. Product Portfolio
        • 10.5.4. SWOT Analysis
        • 10.5.5. Key Strategies and Developments
      • 10.6. Immunocore
        • 10.6.1. Company Overview
        • 10.6.2. Financial Highlights
        • 10.6.3. Product Portfolio
        • 10.6.4. SWOT Analysis
        • 10.6.5. Key Strategies and Developments
      • 10.7. Kuur Therapeutics Limited
        • 10.7.1. Company Overview
        • 10.7.2. Financial Highlights
        • 10.7.3. Product Portfolio
        • 10.7.4. SWOT Analysis
        • 10.7.5. Key Strategies and Developments
      • 10.8. Lion TCR Pte. Ltd.
        • 10.8.1. Company Overview
        • 10.8.2. Financial Highlights
        • 10.8.3. Product Portfolio
        • 10.8.4. SWOT Analysis
        • 10.8.5. Key Strategies and Developments
      • 10.9. Kite Pharma (A Gilead Sciences Company)
        • 10.9.1. Company Overview
        • 10.9.2. Financial Highlights
        • 10.9.3. Product Portfolio
        • 10.9.4. SWOT Analysis
        • 10.9.5. Key Strategies and Developments
      • 10.10. Takara Bio Inc.
        • 10.10.1. Company Overview
        • 10.10.2. Financial Highlights
        • 10.10.3. Product Portfolio
        • 10.10.4. SWOT Analysis
        • 10.10.5. Key Strategies and Developments
      • 10.11. Ziopharm Oncology Inc.
        • 10.11.1. Company Overview
        • 10.11.2. Financial Highlights
        • 10.11.3. Product Portfolio
        • 10.11.4. SWOT Analysis
        • 10.11.5. Key Strategies and Developments
      • 10.12. Merck & Co. Inc.
        • 10.12.1. Company Overview
        • 10.12.2. Financial Highlights
        • 10.12.3. Product Portfolio
        • 10.12.4. SWOT Analysis
        • 10.12.5. Key Strategies and Developments
      • 10.13. Juno Therapeutics
        • 10.13.1. Company Overview
        • 10.13.2. Financial Highlights
        • 10.13.3. Product Portfolio
        • 10.13.4. SWOT Analysis
        • 10.13.5. Key Strategies and Developments
      • 10.14. Others.
        • 10.14.1. Company Overview
        • 10.14.2. Financial Highlights
        • 10.14.3. Product Portfolio
        • 10.14.4. SWOT Analysis
        • 10.14.5. Key Strategies and Developments
    • 11. Assumptions and Acronyms
    • 12. Research Methodology
    • 13. Contact

     

    • List of Figures
      • Figure 1: Global TCR-Based Antibody Revenue (US$ Mn) Market Share by Target Antigen in 2022
      • Figure 2: Global TCR-Based Antibody Market Attractiveness Analysis by Target Antigen, 2016-2032
      • Figure 3: Global TCR-Based Antibody Revenue (US$ Mn) Market Share by Indicationin 2022
      • Figure 4: Global TCR-Based Antibody Market Attractiveness Analysis by Indication, 2016-2032
      • Figure 5: Global TCR-Based Antibody Revenue (US$ Mn) Market Share by End-Usersin 2022
      • Figure 6: Global TCR-Based Antibody Market Attractiveness Analysis by End-Users, 2016-2032
      • Figure 7: Global TCR-Based Antibody Revenue (US$ Mn) Market Share by Region in 2022
      • Figure 8: Global TCR-Based Antibody Market Attractiveness Analysis by Region, 2016-2032
      • Figure 9: Global TCR-Based Antibody Market Revenue (US$ Mn) (2016-2032)
      • Figure 10: Global TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Region (2016-2032)
      • Figure 11: Global TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Target Antigen (2016-2032)
      • Figure 12: Global TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Indication (2016-2032)
      • Figure 13: Global TCR-Based Antibody Market Revenue (US$ Mn) Comparison by End-Users (2016-2032)
      • Figure 14: Global TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
      • Figure 15: Global TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Target Antigen (2016-2032)
      • Figure 16: Global TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Indication (2016-2032)
      • Figure 17: Global TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by End-Users (2016-2032)
      • Figure 18: Global TCR-Based Antibody Market Share Comparison by Region (2016-2032)
      • Figure 19: Global TCR-Based Antibody Market Share Comparison by Target Antigen (2016-2032)
      • Figure 20: Global TCR-Based Antibody Market Share Comparison by Indication (2016-2032)
      • Figure 21: Global TCR-Based Antibody Market Share Comparison by End-Users (2016-2032)
      • Figure 22: North America TCR-Based Antibody Revenue (US$ Mn) Market Share by Target Antigenin 2022
      • Figure 23: North America TCR-Based Antibody Market Attractiveness Analysis by Target Antigen, 2016-2032
      • Figure 24: North America TCR-Based Antibody Revenue (US$ Mn) Market Share by Indicationin 2022
      • Figure 25: North America TCR-Based Antibody Market Attractiveness Analysis by Indication, 2016-2032
      • Figure 26: North America TCR-Based Antibody Revenue (US$ Mn) Market Share by End-Usersin 2022
      • Figure 27: North America TCR-Based Antibody Market Attractiveness Analysis by End-Users, 2016-2032
      • Figure 28: North America TCR-Based Antibody Revenue (US$ Mn) Market Share by Country in 2022
      • Figure 29: North America TCR-Based Antibody Market Attractiveness Analysis by Country, 2016-2032
      • Figure 30: North America TCR-Based Antibody Market Revenue (US$ Mn) (2016-2032)
      • Figure 31: North America TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Figure 32: North America TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Target Antigen (2016-2032)
      • Figure 33: North America TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Indication (2016-2032)
      • Figure 34: North America TCR-Based Antibody Market Revenue (US$ Mn) Comparison by End-Users (2016-2032)
      • Figure 35: North America TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Figure 36: North America TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Target Antigen (2016-2032)
      • Figure 37: North America TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Indication (2016-2032)
      • Figure 38: North America TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by End-Users (2016-2032)
      • Figure 39: North America TCR-Based Antibody Market Share Comparison by Country (2016-2032)
      • Figure 40: North America TCR-Based Antibody Market Share Comparison by Target Antigen (2016-2032)
      • Figure 41: North America TCR-Based Antibody Market Share Comparison by Indication (2016-2032)
      • Figure 42: North America TCR-Based Antibody Market Share Comparison by End-Users (2016-2032)
      • Figure 43: Europe TCR-Based Antibody Revenue (US$ Mn) Market Share by Target Antigenin 2022
      • Figure 44: Europe TCR-Based Antibody Market Attractiveness Analysis by Target Antigen, 2016-2032
      • Figure 45: Europe TCR-Based Antibody Revenue (US$ Mn) Market Share by Indicationin 2022
      • Figure 46: Europe TCR-Based Antibody Market Attractiveness Analysis by Indication, 2016-2032
      • Figure 47: Europe TCR-Based Antibody Revenue (US$ Mn) Market Share by End-Usersin 2022
      • Figure 48: Europe TCR-Based Antibody Market Attractiveness Analysis by End-Users, 2016-2032
      • Figure 49: Europe TCR-Based Antibody Revenue (US$ Mn) Market Share by Country in 2022
      • Figure 50: Europe TCR-Based Antibody Market Attractiveness Analysis by Country, 2016-2032
      • Figure 51: Europe TCR-Based Antibody Market Revenue (US$ Mn) (2016-2032)
      • Figure 52: Europe TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Figure 53: Europe TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Target Antigen (2016-2032)
      • Figure 54: Europe TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Indication (2016-2032)
      • Figure 55: Europe TCR-Based Antibody Market Revenue (US$ Mn) Comparison by End-Users (2016-2032)
      • Figure 56: Europe TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Figure 57: Europe TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Target Antigen (2016-2032)
      • Figure 58: Europe TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Indication (2016-2032)
      • Figure 59: Europe TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by End-Users (2016-2032)
      • Figure 60: Europe TCR-Based Antibody Market Share Comparison by Country (2016-2032)
      • Figure 61: Europe TCR-Based Antibody Market Share Comparison by Target Antigen (2016-2032)
      • Figure 62: Europe TCR-Based Antibody Market Share Comparison by Indication (2016-2032)
      • Figure 63: Europe TCR-Based Antibody Market Share Comparison by End-Users (2016-2032)
      • Figure 64: Asia-Pacific TCR-Based Antibody Revenue (US$ Mn) Market Share by Target Antigenin 2022
      • Figure 65: Asia-Pacific TCR-Based Antibody Market Attractiveness Analysis by Target Antigen, 2016-2032
      • Figure 66: Asia-Pacific TCR-Based Antibody Revenue (US$ Mn) Market Share by Indicationin 2022
      • Figure 67: Asia-Pacific TCR-Based Antibody Market Attractiveness Analysis by Indication, 2016-2032
      • Figure 68: Asia-Pacific TCR-Based Antibody Revenue (US$ Mn) Market Share by End-Usersin 2022
      • Figure 69: Asia-Pacific TCR-Based Antibody Market Attractiveness Analysis by End-Users, 2016-2032
      • Figure 70: Asia-Pacific TCR-Based Antibody Revenue (US$ Mn) Market Share by Country in 2022
      • Figure 71: Asia-Pacific TCR-Based Antibody Market Attractiveness Analysis by Country, 2016-2032
      • Figure 72: Asia-Pacific TCR-Based Antibody Market Revenue (US$ Mn) (2016-2032)
      • Figure 73: Asia-Pacific TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Figure 74: Asia-Pacific TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Target Antigen (2016-2032)
      • Figure 75: Asia-Pacific TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Indication (2016-2032)
      • Figure 76: Asia-Pacific TCR-Based Antibody Market Revenue (US$ Mn) Comparison by End-Users (2016-2032)
      • Figure 77: Asia-Pacific TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Figure 78: Asia-Pacific TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Target Antigen (2016-2032)
      • Figure 79: Asia-Pacific TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Indication (2016-2032)
      • Figure 80: Asia-Pacific TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by End-Users (2016-2032)
      • Figure 81: Asia-Pacific TCR-Based Antibody Market Share Comparison by Country (2016-2032)
      • Figure 82: Asia-Pacific TCR-Based Antibody Market Share Comparison by Target Antigen (2016-2032)
      • Figure 83: Asia-Pacific TCR-Based Antibody Market Share Comparison by Indication (2016-2032)
      • Figure 84: Asia-Pacific TCR-Based Antibody Market Share Comparison by End-Users (2016-2032)
      • Figure 85: South America TCR-Based Antibody Revenue (US$ Mn) Market Share by Target Antigenin 2022
      • Figure 86: South America TCR-Based Antibody Market Attractiveness Analysis by Target Antigen, 2016-2032
      • Figure 87: South America TCR-Based Antibody Revenue (US$ Mn) Market Share by Indicationin 2022
      • Figure 88: South America TCR-Based Antibody Market Attractiveness Analysis by Indication, 2016-2032
      • Figure 89: South America TCR-Based Antibody Revenue (US$ Mn) Market Share by End-Usersin 2022
      • Figure 90: South America TCR-Based Antibody Market Attractiveness Analysis by End-Users, 2016-2032
      • Figure 91: South America TCR-Based Antibody Revenue (US$ Mn) Market Share by Country in 2022
      • Figure 92: South America TCR-Based Antibody Market Attractiveness Analysis by Country, 2016-2032
      • Figure 93: South America TCR-Based Antibody Market Revenue (US$ Mn) (2016-2032)
      • Figure 94: South America TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Figure 95: South America TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Target Antigen (2016-2032)
      • Figure 96: South America TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Indication (2016-2032)
      • Figure 97: South America TCR-Based Antibody Market Revenue (US$ Mn) Comparison by End-Users (2016-2032)
      • Figure 98: South America TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Figure 99: South America TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Target Antigen (2016-2032)
      • Figure 100: South America TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Indication (2016-2032)
      • Figure 101: South America TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by End-Users (2016-2032)
      • Figure 102: South America TCR-Based Antibody Market Share Comparison by Country (2016-2032)
      • Figure 103: South America TCR-Based Antibody Market Share Comparison by Target Antigen (2016-2032)
      • Figure 104: South America TCR-Based Antibody Market Share Comparison by Indication (2016-2032)
      • Figure 105: South America TCR-Based Antibody Market Share Comparison by End-Users (2016-2032)
      • Figure 106: Middle East and Africa TCR-Based Antibody Revenue (US$ Mn) Market Share by Target Antigenin 2022
      • Figure 107: Middle East and Africa TCR-Based Antibody Market Attractiveness Analysis by Target Antigen, 2016-2032
      • Figure 108: Middle East and Africa TCR-Based Antibody Revenue (US$ Mn) Market Share by Indicationin 2022
      • Figure 109: Middle East and Africa TCR-Based Antibody Market Attractiveness Analysis by Indication, 2016-2032
      • Figure 110: Middle East and Africa TCR-Based Antibody Revenue (US$ Mn) Market Share by End-Usersin 2022
      • Figure 111: Middle East and Africa TCR-Based Antibody Market Attractiveness Analysis by End-Users, 2016-2032
      • Figure 112: Middle East and Africa TCR-Based Antibody Revenue (US$ Mn) Market Share by Country in 2022
      • Figure 113: Middle East and Africa TCR-Based Antibody Market Attractiveness Analysis by Country, 2016-2032
      • Figure 114: Middle East and Africa TCR-Based Antibody Market Revenue (US$ Mn) (2016-2032)
      • Figure 115: Middle East and Africa TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Figure 116: Middle East and Africa TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Target Antigen (2016-2032)
      • Figure 117: Middle East and Africa TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Indication (2016-2032)
      • Figure 118: Middle East and Africa TCR-Based Antibody Market Revenue (US$ Mn) Comparison by End-Users (2016-2032)
      • Figure 119: Middle East and Africa TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Figure 120: Middle East and Africa TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Target Antigen (2016-2032)
      • Figure 121: Middle East and Africa TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Indication (2016-2032)
      • Figure 122: Middle East and Africa TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by End-Users (2016-2032)
      • Figure 123: Middle East and Africa TCR-Based Antibody Market Share Comparison by Country (2016-2032)
      • Figure 124: Middle East and Africa TCR-Based Antibody Market Share Comparison by Target Antigen (2016-2032)
      • Figure 125: Middle East and Africa TCR-Based Antibody Market Share Comparison by Indication (2016-2032)
      • Figure 126: Middle East and Africa TCR-Based Antibody Market Share Comparison by End-Users (2016-2032)

       

    • List of Tables
      • Table 1: Global TCR-Based Antibody Market Comparison by Target Antigen (2016-2032)
      • Table 2: Global TCR-Based Antibody Market Comparison by Indication (2016-2032)
      • Table 3: Global TCR-Based Antibody Market Comparison by End-Users (2016-2032)
      • Table 4: Global TCR-Based Antibody Revenue (US$ Mn) Comparison by Region (2016-2032)
      • Table 5: Global TCR-Based Antibody Market Revenue (US$ Mn) (2016-2032)
      • Table 6: Global TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Region (2016-2032)
      • Table 7: Global TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Target Antigen (2016-2032)
      • Table 8: Global TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Indication (2016-2032)
      • Table 9: Global TCR-Based Antibody Market Revenue (US$ Mn) Comparison by End-Users (2016-2032)
      • Table 10: Global TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
      • Table 11: Global TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Target Antigen (2016-2032)
      • Table 12: Global TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Indication (2016-2032)
      • Table 13: Global TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by End-Users (2016-2032)
      • Table 14: Global TCR-Based Antibody Market Share Comparison by Region (2016-2032)
      • Table 15: Global TCR-Based Antibody Market Share Comparison by Target Antigen (2016-2032)
      • Table 16: Global TCR-Based Antibody Market Share Comparison by Indication (2016-2032)
      • Table 17: Global TCR-Based Antibody Market Share Comparison by End-Users (2016-2032)
      • Table 18: North America TCR-Based Antibody Market Comparison by Indication (2016-2032)
      • Table 19: North America TCR-Based Antibody Market Comparison by End-Users (2016-2032)
      • Table 20: North America TCR-Based Antibody Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 21: North America TCR-Based Antibody Market Revenue (US$ Mn) (2016-2032)
      • Table 22: North America TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 23: North America TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Target Antigen (2016-2032)
      • Table 24: North America TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Indication (2016-2032)
      • Table 25: North America TCR-Based Antibody Market Revenue (US$ Mn) Comparison by End-Users (2016-2032)
      • Table 26: North America TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 27: North America TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Target Antigen (2016-2032)
      • Table 28: North America TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Indication (2016-2032)
      • Table 29: North America TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by End-Users (2016-2032)
      • Table 30: North America TCR-Based Antibody Market Share Comparison by Country (2016-2032)
      • Table 31: North America TCR-Based Antibody Market Share Comparison by Target Antigen (2016-2032)
      • Table 32: North America TCR-Based Antibody Market Share Comparison by Indication (2016-2032)
      • Table 33: North America TCR-Based Antibody Market Share Comparison by End-Users (2016-2032)
      • Table 34: Europe TCR-Based Antibody Market Comparison by Target Antigen (2016-2032)
      • Table 35: Europe TCR-Based Antibody Market Comparison by Indication (2016-2032)
      • Table 36: Europe TCR-Based Antibody Market Comparison by End-Users (2016-2032)
      • Table 37: Europe TCR-Based Antibody Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 38: Europe TCR-Based Antibody Market Revenue (US$ Mn) (2016-2032)
      • Table 39: Europe TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 40: Europe TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Target Antigen (2016-2032)
      • Table 41: Europe TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Indication (2016-2032)
      • Table 42: Europe TCR-Based Antibody Market Revenue (US$ Mn) Comparison by End-Users (2016-2032)
      • Table 43: Europe TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 44: Europe TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Target Antigen (2016-2032)
      • Table 45: Europe TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Indication (2016-2032)
      • Table 46: Europe TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by End-Users (2016-2032)
      • Table 47: Europe TCR-Based Antibody Market Share Comparison by Country (2016-2032)
      • Table 48: Europe TCR-Based Antibody Market Share Comparison by Target Antigen (2016-2032)
      • Table 49: Europe TCR-Based Antibody Market Share Comparison by Indication (2016-2032)
      • Table 50: Europe TCR-Based Antibody Market Share Comparison by End-Users (2016-2032)
      • Table 51: Asia-Pacific TCR-Based Antibody Market Comparison by Target Antigen (2016-2032)
      • Table 52: Asia-Pacific TCR-Based Antibody Market Comparison by Indication (2016-2032)
      • Table 53: Asia-Pacific TCR-Based Antibody Market Comparison by End-Users (2016-2032)
      • Table 54: Asia-Pacific TCR-Based Antibody Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 55: Asia-Pacific TCR-Based Antibody Market Revenue (US$ Mn) (2016-2032)
      • Table 56: Asia-Pacific TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 57: Asia-Pacific TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Target Antigen (2016-2032)
      • Table 58: Asia-Pacific TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Indication (2016-2032)
      • Table 59: Asia-Pacific TCR-Based Antibody Market Revenue (US$ Mn) Comparison by End-Users (2016-2032)
      • Table 60: Asia-Pacific TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 61: Asia-Pacific TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Target Antigen (2016-2032)
      • Table 62: Asia-Pacific TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Indication (2016-2032)
      • Table 63: Asia-Pacific TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by End-Users (2016-2032)
      • Table 64: Asia-Pacific TCR-Based Antibody Market Share Comparison by Country (2016-2032)
      • Table 65: Asia-Pacific TCR-Based Antibody Market Share Comparison by Target Antigen (2016-2032)
      • Table 66: Asia-Pacific TCR-Based Antibody Market Share Comparison by Indication (2016-2032)
      • Table 67: Asia-Pacific TCR-Based Antibody Market Share Comparison by End-Users (2016-2032)
      • Table 68: South America TCR-Based Antibody Market Comparison by Target Antigen (2016-2032)
      • Table 69: South America TCR-Based Antibody Market Comparison by Indication (2016-2032)
      • Table 70: South America TCR-Based Antibody Market Comparison by End-Users (2016-2032)
      • Table 71: South America TCR-Based Antibody Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 72: South America TCR-Based Antibody Market Revenue (US$ Mn) (2016-2032)
      • Table 73: South America TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 74: South America TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Target Antigen (2016-2032)
      • Table 75: South America TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Indication (2016-2032)
      • Table 76: South America TCR-Based Antibody Market Revenue (US$ Mn) Comparison by End-Users (2016-2032)
      • Table 77: South America TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 78: South America TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Target Antigen (2016-2032)
      • Table 79: South America TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Indication (2016-2032)
      • Table 80: South America TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by End-Users (2016-2032)
      • Table 81: South America TCR-Based Antibody Market Share Comparison by Country (2016-2032)
      • Table 82: South America TCR-Based Antibody Market Share Comparison by Target Antigen (2016-2032)
      • Table 83: South America TCR-Based Antibody Market Share Comparison by Indication (2016-2032)
      • Table 84: South America TCR-Based Antibody Market Share Comparison by End-Users (2016-2032)
      • Table 85: Middle East and Africa TCR-Based Antibody Market Comparison by Target Antigen (2016-2032)
      • Table 86: Middle East and Africa TCR-Based Antibody Market Comparison by Indication (2016-2032)
      • Table 87: Middle East and Africa TCR-Based Antibody Market Comparison by End-Users (2016-2032)
      • Table 88: Middle East and Africa TCR-Based Antibody Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 89: Middle East and Africa TCR-Based Antibody Market Revenue (US$ Mn) (2016-2032)
      • Table 90: Middle East and Africa TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Country (2016-2032)
      • Table 91: Middle East and Africa TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Target Antigen (2016-2032)
      • Table 92: Middle East and Africa TCR-Based Antibody Market Revenue (US$ Mn) Comparison by Indication (2016-2032)
      • Table 93: Middle East and Africa TCR-Based Antibody Market Revenue (US$ Mn) Comparison by End-Users (2016-2032)
      • Table 94: Middle East and Africa TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
      • Table 95: Middle East and Africa TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Target Antigen (2016-2032)
      • Table 96: Middle East and Africa TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by Indication (2016-2032)
      • Table 97: Middle East and Africa TCR-Based Antibody Market Y-o-Y Growth Rate Comparison by End-Users (2016-2032)
      • Table 98: Middle East and Africa TCR-Based Antibody Market Share Comparison by Country (2016-2032)
      • Table 99: Middle East and Africa TCR-Based Antibody Market Share Comparison by Target Antigen (2016-2032)
      • Table 100: Middle East and Africa TCR-Based Antibody Market Share Comparison by Indication (2016-2032)
      • Table 101: Middle East and Africa TCR-Based Antibody Market Share Comparison by End-Users (2016-2032)
    • GlaxoSmithKline
    • Adaptimmune Therapeutics PLC
    • Celgene Corporation
    • Immunocore
    • Kuur Therapeutics Limited
    • Lion TCR Pte. Ltd.
    • Kite Pharma (A Gilead Sciences Company)
    • Takara Bio Inc.
    • Ziopharm Oncology Inc.
    • Merck & Co. Inc.
    • Juno Therapeutics
    • Others.
  • settingsSettings

Related Reports

Our Clients

  • Our Clients
Inquiry Before Buying

TCR-Based Antibody Market
  • 84335
  • Feb 2022
    • ★★★★★
      ★★★★★
    • (95)
  • US $5,999
    US $2,999
  • US $7,999
    US $3,499
  • US $12,999
    US $4,499
Buy Now
✖
Request a Sample Report
We'll get back to you as quickly as possible

Single User
$5,999
$2,999
USD / per unit
save 50%
 Multi User
$7,999
$3,499
USD / per unit
save 55%
 Corporate User
$12,999
$4,499
USD / per unit
save 65%
e-Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization No up to 10 hrs work up to 30 hrs work
Accessibility 1 User 2-5 User Unlimited
Analyst Support up to 20 hrs up to 40 hrs up to 50 hrs
Benefit Up to 20% off on next purchase Up to 25% off on next purchase Up to 30% off on next purchase
Buy Now ($ 2,999)Buy Now ($ 3,499)Buy Now ($ 4,499)
auto undefined
af Afrikaanssq Albanianam Amharicar Arabichy Armenianaz Azerbaijanieu Basquebe Belarusianbn Bengalibs Bosnianbg Bulgarianca Catalanceb Cebuanony Chichewazh-CN Chinese (Simplified)zh-TW Chinese (Traditional)co Corsicanhr Croatiancs Czechda Danishnl Dutchen Englisheo Esperantoet Estoniantl Filipinofi Finnishfr Frenchfy Frisiangl Galicianka Georgiande Germanel Greekgu Gujaratiht Haitian Creoleha Hausahaw Hawaiianiw Hebrewhi Hindihmn Hmonghu Hungarianis Icelandicig Igboid Indonesianga Irishit Italianja Japanesejw Javanesekn Kannadakk Kazakhkm Khmerko Koreanku Kurdish (Kurmanji)ky Kyrgyzlo Laola Latinlv Latvianlt Lithuanianlb Luxembourgishmk Macedonianmg Malagasyms Malayml Malayalammt Maltesemi Maorimr Marathimn Mongolianmy Myanmar (Burmese)ne Nepalino Norwegianps Pashtofa Persianpl Polishpt Portuguesepa Punjabiro Romanianru Russiansm Samoangd Scottish Gaelicsr Serbianst Sesothosn Shonasd Sindhisi Sinhalask Slovaksl Slovenianso Somalies Spanishsu Sundanesesw Swahilisv Swedishtg Tajikta Tamilte Teluguth Thaitr Turkishuk Ukrainianur Urduuz Uzbekvi Vietnamesecy Welshxh Xhosayi Yiddishyo Yorubazu Zulu
Find Help
Legal
Explore